Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
World Journal of Surgical Oncology
Published in: World Journal of Surgical Oncology 1/2014

Open Access 01-12-2014 | Research

Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk

Authors: Xiao Wang, Yi-wei Lin, Jian Wu, Yi Zhu, Xiang-lai Xu, Xin Xu, Zhen Liang, Zheng-hui Hu, Shi-qi Li, Xiang-yi Zheng, Li-ping Xie

Published in: World Journal of Surgical Oncology | Issue 1/2014

Login to get access

Abstract

Background

Epidemiological studies of the association between nonsteroidal anti-inflammatory drug (NSAID) intake and the risk of prostate cancer still remain controversial. Therefore, we conducted a meta-analysis to evaluate the potential association between NSAID intake and prostate cancer risk.

Methods

Eligible studies were retrieved by both computerized searches and reviews of references. Subgroup analyses on country and design of study were also performed. Random or fixed-effect models were used to pool estimates of odds ratios (ORs) with 95% confidence intervals (CIs).

Results

We observed that the intake of aspirin was associated with a marginally decreased risk of prostate cancer (OR =0.95, 95% CI =0.93 to 0.98). A similar result was found between nonaspirin NSAIDs and prostate cancer risk (OR =0.94, 95% CI =0.90 to 0.98). However, a positive relation between all-NSAID intake and prostate cancer risk was observed (OR =1.18, 95% CI =1.15 to 1.22).

Conclusions

We observed a marginally inverse correlation between the intake of aspirin and prostate cancer risk. On the contrary, a positive relationship between all-NSAID intake and prostate cancer was detected. Further research needs to be conducted to better clarify potential biological mechanisms.
Appendix
Available only for authorised users
Literature
1.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63 (1): 11-30. 10.3322/caac.21166.CrossRefPubMed
2.
Belpomme D, Irigaray P, Ossondo M, Vacque D, Martin M: Prostate cancer as an environmental disease: an ecological study in the French Caribbean islands, Martinique and Guadeloupe. Int J Oncol. 2009, 34 (4): 1037-1044.CrossRefPubMed
3.
Wang X, Wang S, Lin YW, Wu J, Chen H, Mao YQ, Zheng XY, Zhou C, Xie LP: Angiotensin-converting enzyme insertion/deletion polymorphism and the risk of prostate cancer in the Han population of China. Med Oncol. 2012, 29 (3): 1964-1971. 10.1007/s12032-011-0051-5.CrossRefPubMed
4.
Quinn M, Babb P: Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I: international comparisons. BJU Int. 2002, 90 (2): 162-173. 10.1046/j.1464-410X.2002.2822.x.CrossRefPubMed
5.
Rostom A, Dube C, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D: NSAIDs and cyclooxygenase-2 inhibitors for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Intern Med. 2007, 146 (5): 376-389. 10.7326/0003-4819-146-5-200703060-00010.CrossRefPubMed
6.
Corley DA, Kerlikowske K, Verma R, Buffler P: Protective association of aspirin/NSAIDs and esophageal cancer: a systematic review and meta-analysis. Gastroenterology. 2003, 124 (1): 47-56. 10.1053/gast.2003.50008.CrossRefPubMed
7.
8.
Vane JR, Bakhle YS, Botting RM: Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998, 38: 97-120. 10.1146/annurev.pharmtox.38.1.97.CrossRefPubMed
9.
Sabichi AL, Lippman SM: COX-2 inhibitors and other NSAIDs in genitourinary cancer. Semin Oncol. 2004, 31 (2 Suppl 7): 36-44.CrossRefPubMed
10.
Mahmud SM, Franco EL, Aprikian AG: Use of NSAIDs and prostate cancer risk: a meta-analysis. Int J Cancer. 2010, 127 (7): 1680-1691. 10.1002/ijc.25186.CrossRefPubMed
11.
Mantel N, Haenszel W: Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959, 22 (4): 719-748.PubMed
12.
DerSimonian R, Laird N: Meta-analysis in clinical trials. Control Clin Trials. 1986, 7 (3): 177-188. 10.1016/0197-2456(86)90046-2.CrossRefPubMed
13.
14.
Egger M, Davey Smith G, Schneider M, Minder C: Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997, 315 (7109): 629-634. 10.1136/bmj.315.7109.629.PubMedCentralCrossRefPubMed
15.
Begg CB, Mazumdar M: Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994, 50 (4): 1088-1101. 10.2307/2533446.CrossRefPubMed
16.
Paganini-Hill A, Chao A, Ross RK, Henderson BE: Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989, 299 (6710): 1247-1250. 10.1136/bmj.299.6710.1247.PubMedCentralCrossRefPubMed
17.
Ratnasinghe LD, Graubard BI, Kahle L, Tangrea JA, Taylor PR, Hawk E: Aspirin use and mortality from cancer in a prospective cohort study. Anticancer Res. 2004, 24 (5B): 3177-3184.PubMed
18.
Leitzmann MF, Stampfer MJ, Ma J, Chan JM, Colditz GA, Willett WC, Giovannucci E: Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol Biomarkers Prev. 2002, 11 (10 Pt 1): 1108-1111.PubMed
19.
Sorensen HT, Friis S, Norgard B, Mellemkjaer L, Blot WJ, McLaughlin JK, Ekbom A, Baron JA: Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003, 88 (11): 1687-1692. 10.1038/sj.bjc.6600945.PubMedCentralCrossRefPubMed
20.
Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ: A population-based study of daily nonsteroidal anti-inflammatory drug use and prostate cancer. Mayo Clin Proc. 2002, 77 (3): 219-225. 10.4065/77.3.219.CrossRefPubMed
21.
Bosetti C, Talamini R, Negri E, Franceschi S, Montella M, La Vecchia C: Aspirin and the risk of prostate cancer. Eur J Cancer Prev. 2006, 15 (1): 43-45. 10.1097/01.cej.0000180665.04335.de.CrossRefPubMed
22.
Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994, 5 (2): 138-146. 10.1097/00001648-199403000-00003.CrossRefPubMed
23.
Dasgupta K, Di Cesar D, Ghosn J, Rajan R, Mahmud S, Rahme E: Association between NSAIDs and prostate cancer occurrence. Cancer J. 2006, 12 (2): 130-135.PubMed
24.
Habel LA, Zhao W, Stanford JL: Daily aspirin use and prostate cancer risk in a large, multiracial cohort in the US. Cancer Causes Control. 2002, 13 (5): 427-434. 10.1023/A:1015788502099.CrossRefPubMed
25.
Nelson JE, Harris RE: Inverse association of prostate cancer and non-steroidal anti-inflammatory drugs (NSAIDs): results of a case–control study. Oncol Rep. 2000, 7 (1): 169-170.PubMed
26.
Mahmud SM, Tanguay S, Begin LR, Franco EL, Aprikian AG: Non-steroidal anti-inflammatory drug use and prostate cancer in a high-risk population. Eur J Cancer Prev. 2006, 15 (2): 158-164. 10.1097/01.cej.0000197451.02604.25.CrossRefPubMed
27.
Veitonmaki T, Tammela TL, Auvinen A, Murtola TJ: Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer. 2013, 49 (4): 938-945. 10.1016/j.ejca.2012.09.030.CrossRefPubMed
28.
Jacobs EJ, Rodriguez C, Mondul AM, Connell CJ, Henley SJ, Calle EE, Thun MJ: A large cohort study of aspirin and other NSAIDs and prostate cancer incidence. J Natl Cancer Inst. 2005, 97 (13): 975-980. 10.1093/jnci/dji173.CrossRefPubMed
29.
Friis S, Sorensen HT, McLaughlin JK, Johnsen SP, Blot WJ, Olsen JH: A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003, 88 (5): 684-688. 10.1038/sj.bjc.6600760.PubMedCentralCrossRefPubMed
30.
Shebl FM, Sakoda LC, Black A, Koshiol J, Andriole GL, Grubb R, Church TR, Chia D, Zhou C, Chu LW, Huang WY, Peters U, Kirsh VA, Chatterjee N, Leitzmann MF, Hayes RB, Hsing AW: Aspirin but not ibuprofen use is associated with reduced risk of prostate cancer: a PLCO study. Br J Cancer. 2012, 107 (1): 207-214. 10.1038/bjc.2012.227.PubMedCentralCrossRefPubMed
31.
Neugut AI, Rosenberg DJ, Ahsan H, Jacobson JS, Wahid N, Hagan M, Rahman MI, Khan ZR, Chen L, Pablos-Mendez A, Shea S: Association between coronary heart disease and cancers of the breast, prostate, and colon. Cancer Epidemiol Biomarkers Prev. 1998, 7 (10): 869-873.PubMed
32.
Murad AS, Smith GD, Lewis SJ, Cox A, Donovan JL, Neal DE, Hamdy FC, Martin RM: A polymorphism in the glucokinase gene that raises plasma fasting glucose, rs1799884, is associated with diabetes mellitus and prostate cancer: findings from a population-based, case-control study (the ProtecT study). Int J Mol Epidemiol Genet. 2010, 1 (3): 175-183.PubMedCentralPubMed
33.
Perron L, Bairati I, Moore L, Meyer F: Dosage, duration and timing of nonsteroidal antiinflammatory drug use and risk of prostate cancer. Int J Cancer. 2003, 106 (3): 409-415. 10.1002/ijc.11250.CrossRefPubMed
34.
Langman MJ, Cheng KK, Gilman EA, Lancashire RJ: Effect of anti-inflammatory drugs on overall risk of common cancer: case–control study in general practice research database. BMJ. 2000, 320 (7250): 1642-1646. 10.1136/bmj.320.7250.1642.PubMedCentralCrossRefPubMed
35.
Irani J, Ravery V, Pariente JL, Chartier-Kastler E, Lechevallier E, Soulie M, Chautard D, Coloby P, Fontaine E, Bladou F, Desgrandchamps F, Haillot O: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. J Urol. 2002, 168 (5): 1985-1988. 10.1016/S0022-5347(05)64277-2.CrossRefPubMed
36.
García Rodríguez LA, González-Pérez A: Inverse association between nonsteroidal anti-inflammatory drugs and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2004, 13 (4): 649-653.PubMed
37.
Dhillon PK, Kenfield SA, Stampfer MJ, Giovannucci EL: Long-term aspirin use and the risk of total, high-grade, regionally advanced and lethal prostate cancer in a prospective cohort of health professionals, 1988-2006. Int J Cancer. 2011, 128 (10): 2444-2452. 10.1002/ijc.25811.PubMedCentralCrossRefPubMed
38.
Norrish AE, Jackson RT, McRae CU: Non-steroidal anti-inflammatory drugs and prostate cancer progression. Int J Cancer. 1998, 77 (4): 511-515. 10.1002/(SICI)1097-0215(19980812)77:4<511::AID-IJC6>3.0.CO;2-X.CrossRefPubMed
39.
Brasky TM, Velicer CM, Kristal AR, Peters U, Potter JD, White E: NSAIDs and prostate cancer risk in the VITamins And Lifestyle (VITAL) cohort. Cancer Epidemiol Biomarkers Prev. 2010, 19 (12): 3185-3188. 10.1158/1055-9965.EPI-10-0942.PubMedCentralCrossRefPubMed
40.
Platz EA, Rohrmann S, Pearson JD, Corrada MM, Watson DJ, De Marzo AM, Landis PK, Metter EJ, Carter HB: NSAIDs and risk of prostate cancer in the Baltimore Longitudinal Study of Aging. Cancer Epidemiol Biomarkers Prev. 2005, 14 (2): 390-396. 10.1158/1055-9965.EPI-04-0532.CrossRefPubMed
41.
Menezes RJ, Swede H, Niles R, Moysich KB: Regular use of aspirin and prostate cancer risk (United States). Cancer Causes Control. 2006, 17 (3): 251-256. 10.1007/s10552-005-0450-z.CrossRefPubMed
42.
Coogan PF, Kelly JP, Strom BL, Rosenberg L: Statin and NSAID use and prostate cancer risk. Pharmacoepidemiol Drug Saf. 2010, 19 (7): 752-755. 10.1002/pds.1970.PubMedCentralCrossRefPubMed
43.
Salinas CA, Kwon EM, FitzGerald LM, Feng Z, Nelson PS, Ostrander EA, Peters U, Stanford JL: Use of aspirin and other nonsteroidal antiinflammatory medications in relation to prostate cancer risk. Am J Epidemiol. 2010, 172 (5): 578-590. 10.1093/aje/kwq175.PubMedCentralCrossRefPubMed
44.
Mahmud SM, Franco EL, Turner D, Platt RW, Beck P, Skarsgard D, Tonita J, Sharpe C, Aprikian AG: Use of non-steroidal anti-inflammatory drugs and prostate cancer risk: a population-based nested case-control study. PLoS One. 2011, 6 (1): e16412-10.1371/journal.pone.0016412.PubMedCentralCrossRefPubMed
45.
Lieberman R: Chemoprevention of prostate cancer: current status and future directions. Cancer Metastasis Rev. 2002, 21 (3–4): 297-309.CrossRefPubMed
46.
47.
Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB: Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA. 2000, 283 (15): 2008-2012. 10.1001/jama.283.15.2008.CrossRefPubMed
Metadata
Title
Meta-analysis of nonsteroidal anti-inflammatory drug intake and prostate cancer risk
Authors
Xiao Wang
Yi-wei Lin
Jian Wu
Yi Zhu
Xiang-lai Xu
Xin Xu
Zhen Liang
Zheng-hui Hu
Shi-qi Li
Xiang-yi Zheng
Li-ping Xie
Publication date
01-12-2014
Publisher
BioMed Central
Published in
World Journal of Surgical Oncology / Issue 1/2014
Electronic ISSN: 1477-7819
DOI
https://doi.org/10.1186/1477-7819-12-304

Other articles of this Issue 1/2014

World Journal of Surgical Oncology 1/2014 Go to the issue

Case report

Diffuse filiform polyposis of the small intestine without inflammatory bowel disease

Case report

An uncommon long-term survival case of primary cardiac leiomyosarcoma

Research

Evaluation of the benefit of using blue dye in addition to indocyanine green fluorescence for sentinel lymph node biopsy in patients with breast cancer

Case report

Synchronous invasive ductal carcinoma and intravascular large B-cell lymphoma of the breast: a case report and review of the literature

Case report

Robotic pancreaticoduodenectomy in a case of duodenal gastrointestinal stromal tumor

Research

Palliative distal gastrectomy offers no survival benefit over gastrojejunostomy for gastric cancer with outlet obstruction: retrospective analysis of an 11-year experience